174 related articles for article (PubMed ID: 37420133)
21. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
22. Correcting for discounting and loss aversion in composite time trade-off.
Lipman SA; Attema AE; Versteegh MM
Health Econ; 2022 Aug; 31(8):1633-1648. PubMed ID: 35474364
[TBL] [Abstract][Full Text] [Related]
23. Randomised comparison of online interviews versus face-to-face interviews to value health states.
Peasgood T; Bourke M; Devlin N; Rowen D; Yang Y; Dalziel K
Soc Sci Med; 2023 Apr; 323():115818. PubMed ID: 36940582
[TBL] [Abstract][Full Text] [Related]
24. A shortcut to mean-based time tradeoff tariffs for the EQ-5D?
Rand-Hendriksen K; Augestad LA; Dahl FA; Kristiansen IS; Stavem K
Med Decis Making; 2012; 32(4):569-77. PubMed ID: 22247424
[TBL] [Abstract][Full Text] [Related]
25. Time trade-off with someone to live for: impact of having significant others on time trade-off valuations of hypothetical health states.
Hansen TM; Stavem K; Rand K
Qual Life Res; 2022 Apr; 31(4):1199-1207. PubMed ID: 34718936
[TBL] [Abstract][Full Text] [Related]
26. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
27. Re-revisiting the Utilities of Health States Worse than Dead: The Problem Remains.
Jakubczyk M
Med Decis Making; 2023; 43(7-8):875-885. PubMed ID: 37846095
[TBL] [Abstract][Full Text] [Related]
28. Valuations of EQ-5D health states: are the United States and United Kingdom different?
Johnson JA; Luo N; Shaw JW; Kind P; Coons SJ
Med Care; 2005 Mar; 43(3):221-8. PubMed ID: 15725978
[TBL] [Abstract][Full Text] [Related]
29. Expect Nothing: The (Lack of) Influence of Subjective Life Expectancy on Valuation of Child Health States.
Lipman SA
Front Health Serv; 2022; 2():803109. PubMed ID: 36925864
[TBL] [Abstract][Full Text] [Related]
30. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
31. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
32. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
Reckers-Droog V; Karimi M; Lipman S; Verstraete J
Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
[TBL] [Abstract][Full Text] [Related]
33. Quality-of-life valuations of advanced breast cancer by New Zealand women.
Milne RJ; Heaton-Brown KH; Hansen P; Thomas D; Harvey V; Cubitt A
Pharmacoeconomics; 2006; 24(3):281-92. PubMed ID: 16519549
[TBL] [Abstract][Full Text] [Related]
34. 'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.
Åström M; Conte H; Berg J; Burström K
Qual Life Res; 2022 Jul; 31(7):2133-2142. PubMed ID: 35201557
[TBL] [Abstract][Full Text] [Related]
35. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
[TBL] [Abstract][Full Text] [Related]
36. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
37. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
38. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
39. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
40. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
